一次情報の記録
決定級トップライン結果
ブリストル・マイヤーズ スクイブ:arlocabtagene autoleucelの第2相QUINTESSENTIAL試験でトップラインが良好
The registrational Phase 2 QUINTESSENTIAL trial met its primary endpoint of overall response rate and key secondary endpoint of complete response rate in quadruple-class exposed relapsed and refractory multiple myeloma patients previously treated with BCMA-targeted therapy. The safety profile was consistent with other CAR T therapies. Results will be presented at an upcoming medical meeting.
主要事実
- 提出
- 2026年9月8日 10:59
- イベント
- トップライン結果
- 方向
- ポジティブ
- 信頼度
- 出典あり
出典の抜粋
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-ta